Virbac: strong rise in sales growth in 2024

(CercleFinance.com) - Animal health company Virbac has published FY 2024 sales of E1,397m, up 7.
5% LFL and 12.1% as reported.

Sales rose by 10% LFL in Europe, 10.2% in North America, 7.4% in Latin America, 7% in East Asia and 6.7% in India, the Middle East and Africa. By contrast, sales in the Pacific region fell by 5.9%.

Q4 sales came to E355m, up 4.1% LFL and 10.5% as reported.

Virbac is targeting LFL sales growth of between 4% and 6% for 2025. The group points out that the impact of the Sasaeah acquisition should represent 1pt of additional growth in 2025.

Virbac cofirms its target of achieving an adjusted Ebit ratio of 20% by 2030 with a level of R&D investment that we plan to gradually bring back to the group's normative and historical level over the next few years, it adds.


Copyright (c) 2025 CercleFinance.com. All rights reserved.